STOK — Stoke Therapeutics, Inc. stock price, charts and financials

QT40Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. (NASDAQ: STOK) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
28.93
+1.02+3.65%
OverviewShort InterestFilings
STOKQT40Stoke Therapeutics, Inc.·NASDAQ
28.93+3.65%
News
Up 3.7% — Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (businesswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MESO+3.19%$14.87FTRE+1.55%$20.28NKTR+1.45%$68.36GHRS+3.50%$28.72RAPP+1.35%$41.95AGIO+2.00%$33.61ZBIO-1.08%$31.97GPCR-1.13%$35.10
Snapshot
Index-P/E-EPS (ttm)-2.83Insider Own21.09%Shs Outstand64.53MPerf Week-1.40%
Market Cap1.87BForward P/E-EPS next Y-3.54Insider Trans-0.42%Shs Float48.45MPerf Month-9.99%
Enterprise Value1.58BPEG-EPS next Q-0.88Inst Own-Short Float23.12%Perf Quarter-4.40%
Income-7.00MP/S10.15EPS this Y-27.89%Inst Trans-Short Ratio12.87Perf Half Y-6.74%
Sales184.00MP/B5.40EPS next Y2.20%ROA-52.77%Short Interest11.20MPerf YTD-8.85%
Book/sh5.36P/C6.37EPS next 5Y-ROE-59.36%52W High40.22 -28.07%Perf Year24.91%
Cash/sh4.54P/FCF-EPS past 3/5Y-ROIC-62.74%52W Low20.32 42.37%Perf 3Y454.21%
Dividend Est.-EV/EBITDA-Sales past 3/5Y148.43% -Gross Margin84.67%Volatility3.65% 4.17%Perf 5Y11.57%
Dividend TTM-EV/Sales8.57EPS Y/Y TTM-102.42%Oper. Margin-809.69%ATR (14)1.35Perf 10Y-
Dividend Ex-Date-Quick Ratio7.69Sales Y/Y TTM-Profit Margin-753.60%RSI (14)41.06Recom2.19
Dividend Gr. 3/5Y-Current Ratio7.69EPS Q/Q-132.50%SMA20-5.47%Beta1.21Target Price51.00
Payout0.00%Debt/Eq0.00Sales Q/Q-35.71%SMA50-5.47%Rel Volume1.08Prev Close27.91
Employees170LT Debt/Eq0.01EarningsNov 03SMA200-9.43%Avg Volume891.93KPrice28.93
IPO DateJun 19, 2019Option/ShortYes / YesEPS/Sales Surpr.-16.98% 90.70%Net Debt/EBITDA0.52Volume960,054Change3.65%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedCanaccord GenuityBuy$36 → $58
Jul-13-26InitiatedGoldman SachsBuy$44
Feb-23-26InitiatedWolfe ResearchOutperform$40
Feb-05-26InitiatedGuggenheimBuy$60
Jan-12-26ReiteratedWedbushOutperform$36
Jan-05-26ReiteratedLoop Capital Markets$35
Jan-05-26ReiteratedCanaccord GenuityBuy$28 → $36
Dec-15-25ReiteratedUBSNeutral$35 → $50
Dec-15-25ReiteratedHC Wainwright & Co.Buy$35 → $50
Nov-05-25ReiteratedCanaccord GenuityBuy$20 → $28
Latest News· Times ET
Sep-16-26
Sep-16-2612:01PM
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)businesswire.com
Sep-04-26
Sep-04-2612:00AM
Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome StudyBenzinga
Sep-03-26
Sep-03-2604:00PM
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16tgurufocus.com
03:30PM
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)businesswire.com
Sep-02-26
Sep-02-2604:00AM
Stoke Therapeutics to Present at the Cantor Global Healthcare Conferencebusinesswire.com
Sep-01-26
Sep-01-2603:31AM
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy CongressBenzinga
Aug-21-26
Aug-21-2611:06AM
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price TargetBenzinga
Aug-19-26
Aug-19-2611:24PM
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOKdefenseworld.net
Aug-18-26
Aug-18-2612:01PM
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)businesswire.com
Aug-17-26
Aug-17-2604:02PM
Stoke Therapeutics' Dravet Trial Tops Enrollment Target With Zero Dropoutsmarketbeat.com
Aug-07-26
Aug-07-2604:20PM
Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha
Aug-05-26
Aug-05-2612:33AM
Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOKdefenseworld.net
Aug-04-26
Aug-04-2611:09PM
Stoke Therapeutics Q2 Earnings Call Highlightsdefenseworld.net
06:07AM
Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price TargetBenzinga
05:28AM
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Resultsbenzinga.com
Company

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue184379——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit184379——————
Selling, General and Administrative Excl. Other674941——————
Research and Development1388982——————
Other Operating Expense001——————
Operating Income-21-101-115——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)141210——————
Net Income Before Taxes-7-89-105——————
Income Taxes
000——————
Consolidated Net Income-7-89-105——————
Net Income From Continuing Operations-7-89-105——————
Net Income-7-89-105——————
EPS (Recurring)-0.12-1.65-2.38——————
EPS (Basic, Before Extraordinaries)-0.12-1.65-2.38——————
EPS (Diluted)-0.12-1.65-2.38——————
EBITDA-5-87-102——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio10.1816.1025.72——————
Gross Margin100.00100.00100.00——————
Operating Margin-11.41-272.97-1,277.78——————
Net Margin-3.80-240.54-1,166.67——————
Shares Outstanding595444——————
Market Capitalization1,873596231——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$42.34$33.70$25.05$16.41$7.76● Close Price0.00M0.78M1.56M2.34M3.13MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ticho BarryCHIEF MEDICAL OFFICERSep 01 '26Sale30.675,545170,06120,110Sep 03
Kaye Edward M. MDDirectorAug 18 '26Sale32.0312,567402,528124,557Aug 18
Ticho BarryCHIEF MEDICAL OFFICERAug 18 '26Sale32.034,767152,69025,655Aug 18
Allan JonathanGENERAL COUNSEL & CORP SECAug 18 '26Sale32.032,86191,64021,225Aug 18
Allan JonathanGENERAL COUNSEL & CORP SECAug 14 '26Option Exercise0.006,000024,086Aug 18
Ticho BarryCHIEF MEDICAL OFFICERAug 14 '26Option Exercise0.0010,000030,422Aug 18
Kaye Edward M. MDDirectorAug 14 '26Option Exercise0.0026,2500137,124Aug 18
Ticho BarryCHIEF MEDICAL OFFICERAug 03 '26Sale29.047,176208,38520,422Aug 05
Ticho BarryCHIEF MEDICAL OFFICERJul 01 '26Sale32.667,228236,06827,598Jul 06
Allan JonathanGENERAL COUNSEL & CORP SECJun 16 '26Sale29.951,45743,63718,086Jun 18
Ticho BarryCHIEF MEDICAL OFFICERJun 01 '26Sale30.581,79554,89134,826Jun 03
Ticho BarryCHIEF MEDICAL OFFICERMay 01 '26Sale32.792,24373,54836,621May 05
Ticho BarryCHIEF MEDICAL OFFICERApr 01 '26Sale32.661,83860,02938,864Apr 03
Allan JonathanGENERAL COUNSEL & CORP SECMar 20 '26Sale33.699,293313,03819,543Mar 24
Ticho BarryCHIEF MEDICAL OFFICERMar 19 '26Option Exercise2.191,3652,98942,163Mar 19
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.